TY - JOUR
T1 - Breast cancer immunotherapy
T2 - Facts and hopes
AU - Emens, Leisha A.
N1 - Funding Information:
L.A. Emens reports receiving commercial research grants from Aduro Biotech, AstraZeneca, Corvus, EMD Serono, Genentech/Roche, and Merck, and is a consultant/advisory board member for Amgen, AstraZeneca, Bayer, Celgene, eTheRNA, Gritstone, Molecuvax, Peregrine, Syndax, and Vaccinex. Under a licensing agreement between Johns Hopkins University and Aduro Biotech, L.A. Emens and the University are entitled to milestone payments and royalty on the sales of the GM-CSF–secreting breast cancer vaccine. The terms of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies.
Funding Information:
L.A. Emens is supported by NIH R25CA171973, the Breast Cancer Research Foundation, and the Bloomberg Foundation.
Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 (PD-1/ PD-L1) antagonists in small numbers of patients with metastatic breast cancer. Clinical activity appears more likely if the tumor is triple negative, PD-L1þ, and/or harbors higher levels of tumor-infiltrating leukocytes. Responses to atezolizumab and pembrolizumab appear to be durable in metastatic triple-negative breast cancer (TNBC), suggesting that these agents may transform the lives of responding patients. Current clinical efforts are focused on developing immunotherapy combinations that convert nonresponders to responders, deepen those responses that do occur, and surmount acquired resistance to immunotherapy. Identifying biomarkers that can predict the potential for response to single-agent immunotherapy, identify the best immunotherapy combinations for a particular patient, and guide salvage immunotherapy in patients with progressive disease are high priorities for clinical development. Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.
AB - Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of programmed cell death-1/programmed death ligand-1 (PD-1/ PD-L1) antagonists in small numbers of patients with metastatic breast cancer. Clinical activity appears more likely if the tumor is triple negative, PD-L1þ, and/or harbors higher levels of tumor-infiltrating leukocytes. Responses to atezolizumab and pembrolizumab appear to be durable in metastatic triple-negative breast cancer (TNBC), suggesting that these agents may transform the lives of responding patients. Current clinical efforts are focused on developing immunotherapy combinations that convert nonresponders to responders, deepen those responses that do occur, and surmount acquired resistance to immunotherapy. Identifying biomarkers that can predict the potential for response to single-agent immunotherapy, identify the best immunotherapy combinations for a particular patient, and guide salvage immunotherapy in patients with progressive disease are high priorities for clinical development. Smart clinical trials testing rational immunotherapy combinations that include robust biomarker evaluations will accelerate clinical progress, moving us closer to effective immunotherapy for almost all patients with breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85041032773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041032773&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-3001
DO - 10.1158/1078-0432.CCR-16-3001
M3 - Review article
C2 - 28801472
AN - SCOPUS:85041032773
SN - 1078-0432
VL - 24
SP - 511
EP - 520
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -